Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1.
about
Immunobiology of hepatocarcinogenesis: Ways to go or almost there?Cancer-associated fibroblasts in hepatocellular carcinomaImmune Checkpoint Modulators: An Emerging Antiglioma ArmamentariumNeutrophils in Cancer: Two Sides of the Same CoinRegulation of epithelial-mesenchymal transition by tumor-associated macrophages in cancerClinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer: A Systematic Review and Meta-AnalysisExploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer ImmunotherapyImmunology of hepatocellular carcinomaImmunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS SitesCurrent advances in immunotherapy for pancreatic cancerNovel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and developmentTherapeutic cancer vaccines: past, present, and futureImmune cell promotion of metastasisMechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissuesCancer-associated fibroblasts in digestive tumorsThe blockade of immune checkpoints in cancer immunotherapyThe PD1:PD-L1/2 Pathway from Discovery to Clinical ImplementationTargeting immune checkpoints in malignant gliomaThe Kynurenine Pathway Is a Double-Edged Sword in Immune-Privileged Sites and in Cancer: Implications for ImmunotherapyPD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinationsTargeting tumor-associated macrophages to combat pancreatic cancerMyeloid cells in hepatocellular carcinomaPD-L1 and Survival in Solid Tumors: A Meta-AnalysisPrevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challengesMolecular classification and novel targets in hepatocellular carcinoma: recent advancementsCoordinated regulation of myeloid cells by tumoursInhibition of T-cell responses by intratumoral hepatic stellate cells contribute to migration and invasion of hepatocellular carcinomaMacrophage diversity enhances tumor progression and metastasisTumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C.Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.Exosomes from Melatonin Treated Hepatocellularcarcinoma Cells Alter the Immunosupression Status through STAT3 Pathway in Macrophages.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategiesTransition of tumor-associated macrophages from MHC class II(hi) to MHC class II(low) mediates tumor progression in mice.Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma.Impact of tumour associated macrophages in pancreatic cancer.Biochemical signaling of PD-1 on T cells and its functional implicationsTumor associated macrophages and neutrophils in tumor progression.B7-H1-expressing antigen-presenting cells mediate polarization of protumorigenic Th22 subsets.CXCL17 expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma.
P2860
Q26738293-A97F9B99-8989-4D25-B536-C66F4BAC9570Q26738536-C1146ED2-8D0E-44CA-87F4-D583154A9513Q26765459-456AC6D3-F31B-43BD-A4EC-14E507CF8711Q26773072-BBDE73E5-91BE-483C-8F79-8FD37637D93BQ26773786-649FAB11-5CDB-4081-8CD2-9CEB3AB7B076Q26778025-D66CC901-B759-45F5-8152-DBF8E727EF3AQ26779184-194AD815-0DF2-4DE6-BEA9-16039C9EBF4DQ26795411-0F1380EE-A912-403E-A3E5-73010CD56057Q26798402-399699CC-4177-4AB4-A883-BC45B1FE1B12Q26830170-29BB8D34-AFCE-4421-9C0D-884E0B8F6094Q26851211-47C5AAE5-5B50-4194-857B-031A1DA09F18Q26863283-D72C7574-290A-495E-81BA-2DC12B706240Q26991724-6F76A521-D56C-4945-871E-F045DA211086Q27003907-12AE6AF0-ECAA-4D6E-8B09-AB22341A2F40Q27022816-84ABE9D8-4084-4BB9-998C-279F66EED948Q27860852-B72A921E-BF89-4AD8-AE4B-B8D25C017CE1Q28066941-8ECBAD6D-F8BE-4F82-9F04-5D32EA13F119Q28072012-BAB9A3E0-44A1-4B72-BD40-8997FB9806A5Q28073631-200D97A4-05A1-46C7-B764-F5087E52E77AQ28075712-C2A3C6ED-16EA-4B99-B599-3B956441EBDBQ28076103-39208257-DFF2-44D2-8A08-162F2D6F7DC2Q28081161-431A2A76-47BB-4BB9-8E44-F150BD4A6325Q28084090-9B927D1A-1982-46BE-98ED-CF55F52AC8F1Q28272678-BF652189-5DA5-4D24-8B57-A525B11CF72AQ28383646-1A97599B-A5CE-4483-82A0-C460DBA72A26Q28395157-7845C61F-D698-441C-BBB3-C68A7822AA5FQ28567794-66805682-E7FE-4CFC-BBA1-A9D05A856D8EQ29615847-F66789F8-68ED-4488-8650-C5754B1EEBBFQ30916013-07F2D45A-8FA8-424E-B746-96142A444773Q33717146-24A3FC80-46B7-49EA-AF58-2CD9FF90E2A6Q33788049-9DE3D0A5-099B-480B-BEE0-9D6CDD05EE23Q33837257-3359CE97-F78C-4C8C-9B75-E69D0276F87BQ33886267-A77EA8D6-F79B-4ADE-918D-8D17EC3FDF9DQ33980750-71313ED4-EF37-44FE-BFDA-D95376BAD631Q34017748-F8D53675-E005-44A8-8D7B-1ED525D854DCQ34049388-EF53717F-7BE4-4924-B85C-57893549BF0AQ34116796-C1C5175D-D22B-4234-A6CD-3783D4D07B2DQ34306107-D916AA99-5BA7-4CED-827C-BF57B8A1B8E1Q34311714-A334C71E-15DD-40ED-AD4D-8ECF0239E6DEQ34323663-2BC6AD01-BD34-4DA7-BAD0-FD76865A2102
P2860
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Activated monocytes in peritum ...... ase progression through PD-L1.
@en
Activated monocytes in peritum ...... ase progression through PD-L1.
@nl
type
label
Activated monocytes in peritum ...... ase progression through PD-L1.
@en
Activated monocytes in peritum ...... ase progression through PD-L1.
@nl
prefLabel
Activated monocytes in peritum ...... ase progression through PD-L1.
@en
Activated monocytes in peritum ...... ase progression through PD-L1.
@nl
P2093
P2860
P356
P1476
Activated monocytes in peritum ...... ease progression through PD-L1
@en
P2093
Changyou Wu
Dong-Ming Kuang
Jing-Ping Zhang
P2860
P304
P356
10.1084/JEM.20082173
P407
P50
P577
2009-05-18T00:00:00Z